Literature DB >> 18024205

Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease.

Wieke H M Verbeek1, Marije S Goerres, B Mary E von Blomberg, Joost J Oudejans, Petra E T Scholten, Muhammed Hadithi, Abdul Al-Toma, Marco W J Schreurs, Chris J J Mulder.   

Abstract

BACKGROUND: Refractory celiac disease (RCD) patients with aberrant, often clonal, intraepithelial T-cells are at high risk for development of enteropathy associated T-cell lymphoma (EATL). Early detection of those patients that actually develop EATL is of utmost importance for curative intervention. AIM: First, to establish an optimal cut-off value for the percentage of aberrant lymphocytes, previously determined based on clinical observations, via reference ranges for aberrant T-cells in the duodenal mucosa of celiac disease patient and control groups. Secondly, to compare aberrancy with intestinal T-cell clonality as a prognostic parameter for EATL development in RCD.
METHODS: Immunophenotyping using flow cytometry was performed on small intestinal biopsy-derived lymphocytes, obtained from distinct celiac disease (CD) patient and control groups (N=167 in total). T-cell clonality in duodenal biopsy specimens was assessed by PCR in RCD, ulcerative jejunitis and EATL patients (N=31 in total).
RESULTS: In 95% of non-refractory CD patients, the highest percentage aberrant T-cells was 20%. Using this cut-off value, EATL development was exclusively seen in RCD with more than 20% aberrant T-cells (median 52% aberrant T-cells, range 27-94%). When compared with T-cell clonality analysis, >20% aberrancy showed a much higher negative predictive value and sensitivity (both 100%) for EATL development in RCD patients than T-cell clonality analysis (respectively 75% and 78%).
CONCLUSIONS: Quantification of aberrant T-cells by flow cytometry is preferable to T-cell clonality analysis for identification of RCD patients at risk for EATL development. A cut-off value of 20% is of use in risk stratification, therapeutic options and subsequent follow-up of RCD patients.

Entities:  

Mesh:

Year:  2007        PMID: 18024205     DOI: 10.1016/j.clim.2007.09.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  37 in total

1.  Evaluation of Cladribine treatment in refractory celiac disease type II.

Authors:  Greetje J Tack; Wieke H M Verbeek; Abdul Al-Toma; Dirk J Kuik; Marco W J Schreurs; Otto Visser; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Classification and management of refractory coeliac disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

3.  Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden.

Authors:  Falko Fend; José Cabecadas; Philippe Gaulard; Elaine S Jaffe; Philip Kluin; Isinsu Kuzu; Loann Peterson; Andrew Wotherspoon; Christer Sundström
Journal:  J Hematop       Date:  2012-09       Impact factor: 0.196

4.  Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease.

Authors:  R L J van Wanrooij; D M J Müller; E A Neefjes-Borst; J Meijer; L G Koudstaal; D A M Heideman; H J Bontkes; B M E von Blomberg; G Bouma; C J J Mulder
Journal:  J Clin Immunol       Date:  2014-07-27       Impact factor: 8.317

5.  Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor.

Authors:  P Nijeboer; Rlj van Wanrooij; T van Gils; N J Wierdsma; G J Tack; B I Witte; H J Bontkes; O Visser; Cjj Mulder; G Bouma
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 6.  Celiac disease: prevalence, diagnosis, pathogenesis and treatment.

Authors:  Naiyana Gujral; Hugh J Freeman; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

Review 7.  Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

Authors:  Udit Chander; Rebecca J Leeman-Neill; Govind Bhagat
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

8.  Clinical staging and survival in refractory celiac disease: a single center experience.

Authors:  Alberto Rubio-Tapia; Darlene G Kelly; Brian D Lahr; Ahmet Dogan; Tsung-Teh Wu; Joseph A Murray
Journal:  Gastroenterology       Date:  2008-10-08       Impact factor: 22.682

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

10.  Emerging therapeutic options for celiac disease: potential alternatives to a gluten-free diet.

Authors:  Anita Bakshi; Sindu Stephen; Marie L Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.